Professional Summary
Professional Overview
Arvind Sreedharan is a seasoned pharmaceutical and biotechnology executive with over two decades of experience in commercial operations, marketing, and business strategy. As the Senior Vice-President at Neurogene Inc., he leverages his deep industry expertise to drive the company's commercial success and strategic growth initiatives.
Experience Summary
Current Role
In his role as Senior Vice-President at Neurogene Inc., Arvind is responsible for leading the company's commercial operations, including product launches, market expansion, and customer engagement strategies. He has been instrumental in establishing Neurogene's presence in the rare disease treatment market and fostering strong partnerships with key stakeholders.
Career Progression
Prior to joining Neurogene, Arvind held various leadership positions at AveXis, Inc. (acquired by Novartis), where he served as Vice President of US Commercial Operations and Vice President of Business Operations. He also brings experience from his roles as Vice President of Marketing at Auspex Pharmaceuticals, Inc. (acquired by Teva) and Director of Marketing at Lundbeck.
Throughout his career, Arvind has consistently demonstrated his ability to drive commercial success, optimize business operations, and lead cross-functional teams to achieve ambitious goals. His track record of guiding companies through strategic transitions and market expansions has earned him a reputation as a highly effective and innovative leader in the pharmaceutical industry.
Academic Background
Arvind holds a bachelor's degree from the University of Illinois at Urbana-Champaign, where he specialized in Biochemistry and Molecular Biology.
Areas of Expertise
- Commercial strategy and operations
- Product launch and market expansion
- Business development and partnerships
- Marketing and brand management
- Rare disease treatment and patient advocacy
- Cross-functional team leadership and collaboration
Professional Impact
During his tenure at AveXis, Arvind played a pivotal role in the successful launch and commercialization of the company's gene therapy for spinal muscular atrophy (SMA), which became a transformative treatment for patients and their families. He also spearheaded the development of comprehensive patient support programs and educational initiatives, resulting in improved access and outcomes for the SMA community.
Conclusion
Arvind Sreedharan's extensive experience and proven track record of driving commercial success in the pharmaceutical and biotechnology industries make him a valuable asset to Neurogene Inc. As the company continues to expand its rare disease treatment portfolio, Arvind's strategic vision, leadership, and deep industry expertise will be instrumental in fueling Neurogene's growth and delivering life-changing therapies to patients in need.
